The study found the 30mg/kg nipocalimab group had a statistically significant durable haemoglobin response by week 24.

The study aims to assess the safety, pharmacodynamics, pharmacokinetics and tolerability of HBM9378 for COPD.

The primary endpoint, change in HbA1C after 36 weeks, was met at all doses.

LTI-03 in idiopathic pulmonary fibrosis (IPF)First patient randomized in the United KingdomClinical trial sites now actively ...

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's ...

Phase II study evaluating 68Ga-FAPI PET uptake heterogeneity as a predictor of T-DXd treatment response in HER2-positive breast cancer brain metastases. This is an ASCO Meeting Abstract from the 2025 ...

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH ...

Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyp ...

For many people with type 2 diabetes, the problem is not just finding a drug that works. It is finding one they can ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...